The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer

被引：65

作者：

Chen, Yaping ^{[1
]}

Zheng, Xiao ^{[1
]}

Wu, Changping ^{[1
,2
]}

机构：

[1] Soochow Univ, Dept Tumor Biol Treatment, Affiliated Hosp 3, Changzhou, Jiangsu, Peoples R China

[2] Soochow Univ, Dept Oncol, Affiliated Hosp 3, Changzhou, Jiangsu, Peoples R China

来源：

FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷

基金：

中国国家自然科学基金;

关键词：

immunotherapy; immune microenvironment; bevacizumab; PD-1; colorectal cancer; KILLER-T-CELLS; ACTIVE SPECIFIC IMMUNOTHERAPY; PHASE-III TRIAL; EPITHELIAL-MESENCHYMAL TRANSITION; BEVACIZUMAB PLUS CAPECITABINE; EXOSOME-DERIVED MICRORNAS; ENDOTHELIAL GROWTH-FACTOR; I CLINICAL-TRIAL; 1ST-LINE TREATMENT; OPEN-LABEL;

D O I：

10.3389/fimmu.2021.792691

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Colorectal cancer (CRC) has the second highest mortality rate among all cancers worldwide. Surgery, chemotherapy, radiotherapy, molecular targeting and other treatment methods have significantly prolonged the survival of patients with CRC. Recently, the emergence of tumor immunotherapy represented by immune checkpoint inhibitors (ICIs) has brought new immunotherapy options for the treatment of advanced CRC. As the efficacy of ICIs is closely related to the tumor immune microenvironment (TME), it is necessary to clarify the relationship between the immune microenvironment of CRC and the efficacy of immunotherapy to ensure that the appropriate drugs are selected. We herein review the latest research progress in the immune microenvironment and strategies related to immunotherapy for CRC. We hope that this review helps in the selection of appropriate treatment strategies for CRC patients.

引用

页数：21

共 290 条

[1] Exosomes with immune modulatory features are present in human breast milk [J].

Admyre, Charlotte ;

Johansson, Sara M. ;

Qazi, Khaleda Rahman ;

Filen, Jan-Jonas ;

Lahesmaa, Riitta ;

Norman, Mikael ;

Neve, Etienne P. A. ;

Scheynius, Annika ;

Gabrielsson, Susanne .

JOURNAL OF IMMUNOLOGY, 2007, 179 (03) :1969-1978

[2] Tumor macrophages are pivotal constructors of tumor collagenous matrix [J].

Afik, Ran ;

Zigmond, Ehud ;

Vugman, Milena ;

Klepfish, Mordehay ;

Shimshoni, Elee ;

Pasmanik-Chor, Metsada ;

Shenoy, Anjana ;

Bassat, Elad ;

Halpern, Zamir ;

Geiger, Tamar ;

Sagi, Irit ;

Varol, Chen .

JOURNAL OF EXPERIMENTAL MEDICINE, 2016, 213 (11) :2315-2331

[3] Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired [J].

Ahmadzadeh, Mojgan ;

Johnson, Laura A. ;

Heemskerk, Bianca ;

Wunderlich, John R. ;

Dudley, Mark E. ;

White, Donald E. ;

Rosenberg, Steven A. .

BLOOD, 2009, 114 (08) :1537-1544

[4] Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation [J].

Anderson, Ana C. ;

Joller, Nicole ;

Kuchroo, Vijay K. .

IMMUNITY, 2016, 44 (05) :989-1004

[5] Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer [J].

Andre, T. ;

Shiu, K-K ;

Kim, T. W. ;

Jensen, B., V ;

Jensen, L. H. ;

Punt, C. ;

Smith, D. ;

Garcia-Carbonero, R. ;

Benavides, M. ;

Gibbs, P. ;

de la Fouchardiere, C. ;

Rivera, F. ;

Elez, E. ;

Bendell, J. ;

Le, D. T. ;

Yoshino, T. ;

Van Cutsem, E. ;

Yang, P. ;

Farooqui, M. Z. H. ;

Marinello, P. ;

Diaz, L. A., Jr. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) :2207-2218

[6] Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study [J].

Antonuzzo, Lorenzo ;

Giommoni, Elisa ;

Pastorelli, Davide ;

Latiano, Tiziana ;

Pavese, Ida ;

Azzarello, Domenico ;

Aieta, Michele ;

Pastina, Ilaria ;

Di Fabio, Francesca ;

Bertolini, Alessandro ;

Corsi, Domenico Cristiano ;

Mogavero, Selene ;

Angelini, Valentina ;

Pazzagli, Mario ;

Di Costanzo, Francesco .

WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (23) :7281-7288

[7] Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis [J].

Ayer Botrel, Tobias Engel ;

de Oliveira Clark, Luciana Gontijo ;

Paladini, Luciano ;

Clark, Otavio Augusto C. .

BMC CANCER, 2016, 16

[8] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study [J].

Balar, Arjun V. ;

Castellano, Daniel ;

O'Donnell, Peter H. ;

Grivas, Petros ;

Vuky, Jacqueline ;

Powles, Thomas ;

Plimack, Elizabeth R. ;

Hahn, Noah M. ;

de Wit, Ronald ;

Pang, Lei ;

Savage, Mary J. ;

Perini, Rodolfo F. ;

Keefe, Stephen M. ;

Bajorin, Dean ;

Bellmunt, Joaquim .

LANCET ONCOLOGY, 2017, 18 (11) :1483-1492

[9] Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer [J].

Balint, Joseph P. ;

Gabitzsch, Elizabeth S. ;

Rice, Adrian ;

Latchman, Yvette ;

Xu, Younong ;

Messerschmidt, Gerald L. ;

Chaudhry, Arvind ;

Morse, Michael A. ;

Jones, Frank R. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (08) :977-987

[10] Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines [J].

Bang, Yeong Hak ;

Kim, Jeong Eun ;

Lee, Ji Sung ;

Kim, Sun Young ;

Kim, Kyu-Pyo ;

Kim, Tae Won ;

Hong, Yong Sang .

SCIENTIFIC REPORTS, 2021, 11 (01)

← 1 2 3 4 5 6 7 8 9 10 →